Indian drugmakers set to capitalize on Cymbalta generics
Approval for the generic version of Eli Lilly’s (NYSE: LLY) Cymbalta duloxetine by the US health regulator (The Pharma Letter December 12, 2013) has come as a shot in the arm for Indian drug majors, who have been waiting for India to pass the Mental Healthcare Bill, reports TPL’s Indian correspondent.
Cymbalta generated sales of $5.08 billion in 2013, of which $3.96 billion came from the USAA. It is prescription medicine used in the treatment of depression and other conditions.
The icing on the cake for Indian drugmakers, however, is the announcement of a national mental health survey to be conducted by the Bangalore based National Institute of Mental Health and Neurosciences, with a pilot study slated to start this month.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze